3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
11
Lung Neoplasms
3
Brain Neoplasms
2
ALK-positive Advanced NSCLC
2
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Neoplasm Metastasis
1
NSCLC
1
Meningioma
1
Lymphoma, Large-Cell, Anaplastic
1
Gastrointestinal Neoplasms
1
Ependymoma
1
Carcinoma, Pancreatic Ductal
1
Carcinoma
1
Breast Neoplasms
1
Interventions
Trastuzumab
304
Paclitaxel
257
Cyclophosphamide
251
Docetaxel
238
Capecitabine
176
Letrozole
163
Carboplatin
163
Fulvestrant
145
Doxorubicin
145
Bevacizumab
121
Anastrozole
106
Tamoxifen
102
exemestane
94
Vinorelbine
91
Epirubicin
90
pertuzumab
89
Gemcitabine
84
Lapatinib
80
Albumin-Bound Paclitaxel
74
Radiotherapy
71
pembrolizumab
70
palbociclib
64
130-nm albumin-bound paclitaxel
58
eribulin
56
Cisplatin
55
Everolimus
49
pyrotinib
45
Taxes
44
Goserelin
43
Neoadjuvant Therapy
40
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Breast Neoplasms
×
brigatinib
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled